OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study determines tumor response rate, time to tumor progression and survival rate at 1
year produced by OSI-774 in previously treated African American patients with nonsmall cell
lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Miguel Villalona Ohio State University Comprehensive Cancer Center